Dr. Jennifer Sherr is currently presenting on @myomnipod Omnipod 5 Automated Insulin Delivery System in Very Young Children with T1D at #ADA2021.
@myomnipod The study was for children 2-5.9 years old. VERY young. #ADA2021
Study included 2-week standard therapy phase followed by 3-month AID phase #ADA2021
Study Cohort:
HbA1c went down
Time in Range increase of 2.5 HOURS per day @myomnipod #ADA2021
@myomnipod TIR increases among all age groups for people on @myomnipod Omnipod 5 is substantial, largest increase among ages 6-13.9 #ADA2021
@myomnipod TIR went up by reducing time in Hyperglycemia and Hypoglycemia #ADA2021
No Severe Hypo or DKA during entire 3-month period #ADA2021
Conclusions: Omnipod 5 is going to be a game changer for those seeking an FDA-approved tubeless Hybrid Closed Loop. #ADA2021
Which patient reported outcomes were they interested in (how are they measuring)?
- PAID: Problem Areas in Diabetes
- PSQI: Pittsburg Sleep Quality Index
- HCS: Hypoglycemic Confidence Scale
- WHO-5: World Health Organization 5
#ADA2021
- PAID: Problem Areas in Diabetes
- PSQI: Pittsburg Sleep Quality Index
- HCS: Hypoglycemic Confidence Scale
- WHO-5: World Health Organization 5
#ADA2021
As noted earlier.... Omnipod 5 led to lower A1C, improved TIR, and minimal hypos. It's a good system. #ADA2021
Conclusions:
- Reduced diabetes-related distress
- Increased hypoglycemic confidence
- Improved sleep quality
- Greater well-being
- Improved quality of life
#ADA2021
- Reduced diabetes-related distress
- Increased hypoglycemic confidence
- Improved sleep quality
- Greater well-being
- Improved quality of life
#ADA2021
Loading suggestions...